126 related articles for article (PubMed ID: 12445230)
1. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma.
Takahashi M; Oka N; Naroda T; Nishitani MA; Kanda K; Kanayama HO; Kagawa S
Int J Urol; 2002 Oct; 9(10):531-8. PubMed ID: 12445230
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma.
Sumi T; Nakatani T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Nakagawa E; Sugimura K; Kawashima H; Ishiko O
Oncol Rep; 2003; 10(3):567-70. PubMed ID: 12684625
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
6. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
[TBL] [Abstract][Full Text] [Related]
7. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
Ueno H; Nakamura H; Inoue M; Imai K; Noguchi M; Sato H; Seiki M; Okada Y
Cancer Res; 1997 May; 57(10):2055-60. PubMed ID: 9158005
[TBL] [Abstract][Full Text] [Related]
8. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.
Tilki D; Nguyen HG; Dall'Era MA; Bertini R; Carballido JA; Chromecki T; Ciancio G; Daneshmand S; Gontero P; Gonzalez J; Haferkamp A; Hohenfellner M; Huang WC; Koppie TM; Lorentz CA; Mandel P; Martinez-Salamanca JI; Master VA; Matloob R; McKiernan JM; Mlynarczyk CM; Montorsi F; Novara G; Pahernik S; Palou J; Pruthi RS; Ramaswamy K; Rodriguez Faba O; Russo P; Shariat SF; Spahn M; Terrone C; Vergho D; Wallen EM; Xylinas E; Zigeuner R; Libertino JA; Evans CP
Eur Urol; 2014 Sep; 66(3):577-83. PubMed ID: 23871402
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of extensive necrosis in renal cell carcinoma.
Collins J; Epstein JI
Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
[TBL] [Abstract][Full Text] [Related]
10. Significance of heat shock protein-27 expression in patients with renal cell carcinoma.
Erkizan O; Kirkali G; Yörükoğlu K; Kirkali Z
Urology; 2004 Sep; 64(3):474-8. PubMed ID: 15351573
[TBL] [Abstract][Full Text] [Related]
11. Cancer-Specific Survival Stratification Derived from Tumor Expression of Tissue Inhibitor of Metalloproteinase-2 in Non-Metastatic Renal Cell Carcinoma.
Beardo P; Truan Cacho D; Izquierdo L; Alcover-Garcia JB; Alcaraz A; Extramiana J; Mallofré C
Pathol Oncol Res; 2019 Jan; 25(1):289-299. PubMed ID: 29103203
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: A case-control study and meta-analysis.
Liu Q; Zhang GW; Zhu CY; Wei JX; Tian X; Li Y; Li XD
Cancer Biomark; 2016; 16(2):281-9. PubMed ID: 26756619
[TBL] [Abstract][Full Text] [Related]
13. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
[TBL] [Abstract][Full Text] [Related]
14. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis.
Miyata Y; Iwata T; Ohba K; Kanda S; Nishikido M; Kanetake H
Clin Cancer Res; 2006 Dec; 12(23):6998-7003. PubMed ID: 17145820
[TBL] [Abstract][Full Text] [Related]
16. Increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion.
Kamiya N; Kishimoto T; Suzuki H; Sekita N; Nagai Y; Oosumi N; Kito H; Tochigi N; Shinbo M; Nemori R; Ichikawa T; Igarashi T; Ito H; Ishikura H
Int J Cancer; 2003 Sep; 106(4):480-485. PubMed ID: 12845641
[TBL] [Abstract][Full Text] [Related]
17. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck.
O-Charoenrat P; Rhys-Evans PH; Eccles SA
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):813-20. PubMed ID: 11448356
[TBL] [Abstract][Full Text] [Related]
19. Low clinical stage renal cell carcinoma: relevance of microvascular tumor invasion as a prognostic parameter.
Gonçalves PD; Srougi M; Dall'lio MF; Leite KR; Ortiz V; Hering F
J Urol; 2004 Aug; 172(2):470-4. PubMed ID: 15247705
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity.
Kato K; Hara A; Kuno T; Kitaori N; Huilan Z; Mori H; Toida M; Shibata T
J Cancer Res Clin Oncol; 2005 Jun; 131(6):340-6. PubMed ID: 15614523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
